CANCER, published by Wiley, stands as a pivotal journal in the field of oncology and cancer research, boasting an impressive impact factor and consistently dynamic growth since its inception in 1948. With an ISSN of 0008-543X and an E-ISSN of 1097-0142, this esteemed journal is recognized for its rigorous peer-reviewed articles, making significant contributions to the understanding of cancer biology, treatment modalities, and clinical practices. CANCER holds a distinguished position in the academic community, securing its placement in the Q1 category for both cancer research and oncology, and ranks within the top percentiles on Scopus, indicating its high impact and relevance. The journal is particularly beneficial for researchers, professionals, and students seeking to stay abreast of the latest advancements in cancer science. By addressing essential research questions and providing pathways for new therapies, CANCER continues to play a crucial role in shaping the future of oncology and improving patient outcomes.

Health Equity is an esteemed open-access journal published by MARY ANN LIEBERT, INC, dedicated to advancing knowledge in the fields of health information management, health policy, and public health. With an E-ISSN of 2473-1242 and a commendable Q1 ranking in multiple categories for 2023, including Health Information Management and Health Policy, this journal stands at the forefront of addressing the complexities of health disparities and promoting equitable healthcare solutions. By providing a platform for original research, critical reviews, and innovative methodologies since its inception in 2017, Health Equity plays a crucial role in facilitating dialogue among scholars, practitioners, and policymakers. The journal's commitment to open access ensures that its valuable content is freely available, fostering collaboration and knowledge dissemination within the global health community. As it converges from 2017 to 2024, Health Equity continues to empower its readership to drive impactful changes in health systems and policies worldwide.

Journal of Geriatric Oncology, published by Elsevier, stands at the intersection of geriatric medicine and oncology, addressing the unique needs and challenges of cancer management in older adults. Since its inception in 2010, this esteemed journal has played a pivotal role in advancing research and clinical practices, aiming to improve the quality of life and treatment outcomes for elderly cancer patients. With its impressive categorization in the 2023 Q2 quartile for both Geriatrics and Gerontology and Oncology, the journal demonstrates a noteworthy impact within its fields, ranking #153 out of 404 in Medicine – Oncology and #45 out of 116 in Medicine – Geriatrics and Gerontology. Researchers and healthcare professionals are encouraged to access critical insights through its rigorous peer-reviewed articles, which offer cutting-edge research findings and clinical applications. As the field continues to evolve, the Journal of Geriatric Oncology remains a vital resource for those dedicated to fostering innovation in geriatric oncology.

The Journal of the National Comprehensive Cancer Network (ISSN: 1540-1405, E-ISSN: 1540-1413) is a premier publication in the field of oncology, established by HARBORSIDE PRESS and running since 2003. This highly respected journal holds a remarkable Q1 ranking in both Medicine (Miscellaneous) and Oncology categories, showcasing its significant influence and contribution to cancer research, with a Scopus ranking placing it within the top 5% of its field (Rank #20 out of 404). Aimed at a diverse audience including researchers, clinicians, and students, the journal publishes a wide range of articles that explore cutting-edge findings, clinical practices, and evidence-based guidelines in cancer care. With its commitment to advancing the understanding and treatment of cancer, it serves as a vital resource for professionals dedicated to improving patient outcomes. Although it does not currently offer open access, its impactful content continues to be a cornerstone for anyone involved in oncology research and practice.

The Indian Journal of Surgical Oncology, published by SPRINGER INDIA, is a vital source of scholarly research and discourse in the fields of oncology and surgery. Since its inception in 2010, the journal has been dedicated to advancing the science and practice of surgical oncology, providing a platform for researchers, clinicians, and educators to disseminate their findings and insights. With an increasing impact factor, the journal currently ranks in the Q4 category in Oncology and Q3 category in Surgery, reflecting its growing influence in the academic community. The journal maintains a focus on high-quality research, clinical studies, and innovative surgical techniques, fostering knowledge exchange among professionals in India and beyond. Although an open access option is not provided, the journal remains an essential repository of information for anyone engaged in the rapidly evolving fields of surgical oncology. For access to groundbreaking research and updates in the discipline, the Indian Journal of Surgical Oncology continues to be an indispensable resource.

The ANNALS OF SURGICAL ONCOLOGY, published by SPRINGER, stands as a leading journal dedicated to advancing the field of surgical oncology. With an ISSN of 1068-9265 and an E-ISSN of 1534-4681, this esteemed publication features high-quality research from 1994 to 2024, contributing significantly to the scientific dialogue surrounding surgical techniques, treatment innovations, and patient outcomes within the oncology community. The journal has earned a prestigious Q1 ranking in Surgery and a Q2 in Oncology for 2023, reflecting its pivotal role in influencing clinical practices and research in these fields. According to Scopus metrics, it ranks #51 out of 551 in Medicine Surgery and #133 out of 404 in Medicine Oncology, underscoring its academic rigor and impact. Despite being a subscription-based journal, the depth of knowledge disseminated through its pages is invaluable for researchers, professionals, and students aiming to stay at the forefront of surgical oncology advancements.

International Journal of Clinical Oncology, published by SPRINGER JAPAN KK, is a leading peer-reviewed journal dedicated to advancing research and clinical practices in the fields of oncology, hematology, and surgery. With its impact factor reflecting its significance and reach in the academic community, this journal serves as a solid platform for researchers, professionals, and students to share and disseminate groundbreaking discoveries and methodologies. Notably, it has secured prestigious rankings in the Q1 category in Medicine (miscellaneous) and Surgery, and Q2 in Hematology and Oncology, illustrating its prominent position in the medical literature. The journal's comprehensive scope addresses pivotal clinical issues from 1996 through 2024, further solidifying its relevance in the ever-evolving landscape of cancer research. Despite not offering open access, the depth and quality of research articles ensure that vital information remains accessible to those committed to improving clinical outcomes in oncology. With a focus on innovative treatments and patient care, the International Journal of Clinical Oncology embodies a commitment to fostering excellence in medical research.

Breast Cancer Research and Treatment, published by Springer, stands as a pivotal journal within the domains of Cancer Research and Oncology, exemplified by its impressive Q2 and Q1 quartile rankings, respectively, in the 2023 category rankings. Since its inception in 1981, this journal has provided a vital platform for disseminating cutting-edge research focused on all aspects of breast cancer, ranging from molecular biology to treatment strategies. With an ISSN of 0167-6806 and E-ISSN of 1573-7217, it captures a broad audience of researchers, clinicians, and students dedicated to improving patient outcomes. The journal emphasizes high-quality, peer-reviewed studies that pave the way for advancements in therapy and direct novel insights into oncological practices. By maintaining a strong ranking in Scopus with percentile placements of 74th in Oncology and 61st in Cancer Research, Brest Cancer Research and Treatment continues to foster innovation and collaboration in the fight against breast cancer.

Cancer Medicine is a leading open access journal published by WILEY, focusing on innovative research and advancements in the fields of Cancer Research, Oncology, and Radiology, with an impressive impact evidenced by its 2023 Q2 ranking in Cancer Research and Q1 rankings in both Oncology and Radiology, Nuclear Medicine and Imaging. With an ISSN of 2045-7634, this journal has been committed to disseminating pivotal findings since its inception in 2012, serving as a vital platform for researchers, practitioners, and students alike. The journal proudly embodies the spirit of open access, ensuring that groundbreaking cancer research is accessible to a global audience. Located in the United Kingdom, it spans a wide array of topics, promising comprehensive insights into cancer therapies, molecular mechanisms, and imaging techniques, thereby significantly contributing to the enhancement of cancer care and treatment outcomes. Researchers interested in exploring the latest advancements in cancer medicine will find this journal an indispensable resource.

Urogynecology, published by Lippincott Williams & Wilkins, is a distinguished journal that serves as an essential platform for researchers, clinicians, and students in the fields of obstetrics, gynecology, surgery, and urology. With an impact factor that places it in the Q2 category in various specialties, the journal emphasizes high-quality, peer-reviewed research that contributes to advancements in women's health and pelvic floor disorders. As an Open Access journal, it is committed to enhancing the accessibility of its content, allowing for broader dissemination of knowledge and fostering collaborative efforts in the medical community. Located in India and addressing a global audience, Urogynecology has quickly established its reputation since its inception in 2022, continuing through its converged years until 2024. It is ranked favorably in Scopus across several medical categories, providing a vital resource for cutting-edge research and clinical practice insights. This journal aims to bridge gaps in knowledge and practice, making it an invaluable asset for anyone dedicated to improving outcomes in urogynecology.